EHC Quote, Financials, Valuation and Earnings

Pediatrix Medical Group has a net margin of 10.41% compared to Encompass Health's net margin of 4.52%. Encompass Health's return on equity of 18.4% beat Pediatrix Medical Group's return on equity of -10.7%.

Encompass Health has a consensus price target of $131.58, signalling upside risk potential of 10.36%. On the other hand Pediatrix Medical Group has an analysts' consensus of $17.14 which suggests that it could grow by 21.41%. Given that Pediatrix Medical Group has higher upside potential than Encompass Health, analysts believe Pediatrix Medical Group is more attractive than Encompass Health.

Encompass Health has a beta of 0.903, which suggesting that the stock is 9.671% less volatile than S&P 500. In comparison Pediatrix Medical Group has a beta of 1.269, suggesting its more volatile than the S&P 500 by 26.911%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.55%. Pediatrix Medical Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health pays 13.78% of its earnings as a dividend. Pediatrix Medical Group pays out -- of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health quarterly revenues are $1.5B, which are larger than Pediatrix Medical Group quarterly revenues of $458.4M. Encompass Health's net income of $151.5M is higher than Pediatrix Medical Group's net income of $20.7M. Notably, Encompass Health's price-to-earnings ratio is 24.63x while Pediatrix Medical Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 2.21x versus 0.60x for Pediatrix Medical Group. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute has a net margin of 10.41% compared to Encompass Health's net margin of -18.76%. Encompass Health's return on equity of 18.4% beat The Oncology Institute's return on equity of -340.01%.

Encompass Health has a consensus price target of $131.58, signalling upside risk potential of 10.36%. On the other hand The Oncology Institute has an analysts' consensus of $7.00 which suggests that it could grow by 169.23%. Given that The Oncology Institute has higher upside potential than Encompass Health, analysts believe The Oncology Institute is more attractive than Encompass Health.

Encompass Health has a beta of 0.903, which suggesting that the stock is 9.671% less volatile than S&P 500. In comparison The Oncology Institute has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.55%. The Oncology Institute offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health pays 13.78% of its earnings as a dividend. The Oncology Institute pays out -- of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health quarterly revenues are $1.5B, which are larger than The Oncology Institute quarterly revenues of $104.4M. Encompass Health's net income of $151.5M is higher than The Oncology Institute's net income of -$19.6M. Notably, Encompass Health's price-to-earnings ratio is 24.63x while The Oncology Institute's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 2.21x versus 0.49x for The Oncology Institute. Usually stocks with elevated PS ratios are considered overvalued.

US Physical Therapy has a net margin of 10.41% compared to Encompass Health's net margin of 6.97%. Encompass Health's return on equity of 18.4% beat US Physical Therapy's return on equity of 4.62%.

Encompass Health has a consensus price target of $131.58, signalling upside risk potential of 10.36%. On the other hand US Physical Therapy has an analysts' consensus of $106.00 which suggests that it could grow by 34.89%. Given that US Physical Therapy has higher upside potential than Encompass Health, analysts believe US Physical Therapy is more attractive than Encompass Health.

Encompass Health has a beta of 0.903, which suggesting that the stock is 9.671% less volatile than S&P 500. In comparison US Physical Therapy has a beta of 1.451, suggesting its more volatile than the S&P 500 by 45.087%.

Encompass Health has a quarterly dividend of $0.17 per share corresponding to a yield of 0.55%. US Physical Therapy offers a yield of 2.27% to investors and pays a quarterly dividend of $0.45 per share. Encompass Health pays 13.78% of its earnings as a dividend. US Physical Therapy pays out 100.3% of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but US Physical Therapy's is not.

Encompass Health quarterly revenues are $1.5B, which are larger than US Physical Therapy quarterly revenues of $183.8M. Encompass Health's net income of $151.5M is higher than US Physical Therapy's net income of $12.8M. Notably, Encompass Health's price-to-earnings ratio is 24.63x while US Physical Therapy's PE ratio is 36.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health is 2.21x versus 1.70x for US Physical Therapy. Usually stocks with elevated PS ratios are considered overvalued.